About This Course
This course on Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC) focuses on patient-centered treatment strategies and the latest developments in intravesical therapies. Participants will learn to effectively stratify risk among intermediate-risk bladder cancer patients, emphasizing patient counseling, quality of life considerations, and personalized treatment approaches. The curriculum covers practical skills such as patient preparation, in-office procedures for low-grade tumors, criteria for performing office-based fulguration, recurrence monitoring, and providing robust patient resources. Additionally, the course explores advanced intravesical therapies, highlighting newly FDA-approved agents, various delivery methods prioritizing patient comfort, and cost-effective treatment options. By integrating current guidelines, biomarkers, and patient counseling strategies, clinicians will gain essential knowledge to improve patient outcomes and effectively manage intermediate-risk NMIBC.